Action of 2',2'-difluorodeoxycytidine on DNA synthesis
- PMID: 1718594
Action of 2',2'-difluorodeoxycytidine on DNA synthesis
Abstract
The action of the new deoxycytidine analogue 2',2'-difluorodeoxycytidine (dFdC) on DNA synthesis was investigated in whole cells and in vitro assay systems with purified DNA polymerases. DNA synthesis in human lymphoblastoid CEM cells was inhibited by dFdC in a concentration-dependent manner that could not be reversed by exogenous deoxynucleosides. The analogue was incorporated into cellular DNA; most of the incorporated dFdC 5'-monophosphate (dFdCMP) residues were in internucleotide linkage. In vitro DNA primer extension assays demonstrated that dFdC 5'-triphosphate (dFdCTP) competed with deoxycytidine triphosphate for incorporation into the C sites of the growing DNA strand. The ratios of the apparent Km values for the incorporation of dFdCTP and dCTP into a C site of M13mp19 DNA were 21.8 and 22.9 for DNA polymerases alpha and epsilon, respectively. The apparent Ki values of dFdCTP were 11.2 microM for DNA polymerase alpha and 14.4 microM for polymerase epsilon. After dFdCMP incorporation, the primer was extended by one deoxynucleotide before a major pause in the polymerization process was observed. This was in contrast to the action of arabinosylcytosine 5'-triphosphate, which caused both DNA polymerases alpha and epsilon to pause at the site of incorporation. The 3'----5' exonuclease activity of DNA polymerase epsilon was essentially unable to excise nucleotides from DNA containing dFdCMP at either the 3'-end or at an internal position, whereas arabinosylcytosine monophosphate was removed from the 3'-terminus at 37% the rate for deoxynucleotides. The cytotoxic activity of dFdC was strongly correlated with the amount of dFdCMP incorporated into cellular DNA. Our results demonstrate qualitative and quantitative differences in the molecular actions of dFdC and arabinosylcytosine on DNA metabolism, but are consistent with an important role for such incorporation in the toxicity of dFdC.
Similar articles
-
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.Cancer Res. 1996 Oct 1;56(19):4453-9. Cancer Res. 1996. PMID: 8813140
-
Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.Cancer Chemother Pharmacol. 2000;45(4):320-8. doi: 10.1007/s002800050047. Cancer Chemother Pharmacol. 2000. PMID: 10755321
-
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.Semin Oncol. 1995 Aug;22(4 Suppl 11):61-7. Semin Oncol. 1995. PMID: 7481847
-
Preclinical characteristics of gemcitabine.Anticancer Drugs. 1995 Dec;6 Suppl 6:7-13. doi: 10.1097/00001813-199512006-00002. Anticancer Drugs. 1995. PMID: 8718419 Review.
-
Cellular pharmacology of gemcitabine.Ann Oncol. 2006 May;17 Suppl 5:v7-12. doi: 10.1093/annonc/mdj941. Ann Oncol. 2006. PMID: 16807468 Review.
Cited by
-
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.Pharm Res. 2013 May;30(5):1400-8. doi: 10.1007/s11095-013-0978-7. Epub 2013 Jan 24. Pharm Res. 2013. PMID: 23344908
-
Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.World J Gastroenterol. 2010 Jul 28;16(28):3567-72. doi: 10.3748/wjg.v16.i28.3567. World J Gastroenterol. 2010. PMID: 20653066 Free PMC article.
-
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.Eur J Clin Pharmacol. 2006 Aug;62(8):681-4. doi: 10.1007/s00228-006-0162-7. Epub 2006 Jun 24. Eur J Clin Pharmacol. 2006. PMID: 16799820
-
The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling.Eur J Med Chem. 2018 Mar 25;148:314-324. doi: 10.1016/j.ejmech.2018.02.017. Epub 2018 Feb 12. Eur J Med Chem. 2018. PMID: 29471120 Free PMC article.
-
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.Invest New Drugs. 2019 Feb;37(1):76-86. doi: 10.1007/s10637-018-0602-0. Epub 2018 Apr 18. Invest New Drugs. 2019. PMID: 29667134 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources